Stories

Heart risk is not shaped by nicotine alone. A review linking full switching from smoking to vaping with lower cardiovascular risk reinforces the central point of harm reduction: combustion is the major driver of disease. The distinction between dual use and complete switching also matters, because public health gains depend on moving away from cigarettes, not simply adding another product. Risk communication should be clear enough to help smokers understand that difference.

When a company built around flavoured vaping products is pushed out by regulation, the impact does not stop at the business itself. It also affects the adults who relied on those products to make switching from cigarettes work. The FDA’s approach to flavours has treated adult preference as a regulatory problem rather than part of why harm reduction succeeds. A market without appealing legal alternatives is not safer if smokers are left with cigarettes.

A material usually associated with medical and technical applications is now entering the nicotine conversation. Bioceramic delivery raises questions about whether product design can change exposure, user experience and the risk profile of nicotine use. That makes it worth studying carefully rather than dismissing as just another nicotine product. Innovation will not replace evidence, but it may expand what harm reduction can offer adults who continue to use nicotine.

Doubt can be manufactured in more than one direction. In nicotine policy, selective evidence and repeated uncertainty can make lower-risk products appear more dangerous than they are, while the risks of continued smoking fade into the background. That matters because public understanding shapes regulation, and regulation shapes whether smokers see switching as credible. Public health should challenge misinformation without becoming a source of it.

Public health authorities are reevaluating nicotine regulation as smoking rates decline worldwide. The focus shifts towards safer oral nicotine pouches as an alternative to vapes. The debate emphasizes managing risks proportionately and avoiding past mistakes. US regulators approved nicotine pouches under a harm reduction context. Studies show pouch users are mainly trying to quit smoking. Concerns about youth uptake and oral health effects persist. Transparent risk communication is crucial. Innovations in product design aim to reduce oral irritation. Regulators face challenges in balancing access for adult smokers and preventing youth uptake. Nicotine pouches are recognized as a harm reduction tool compared to cigarettes, highlighting the need for evidence-based regulation promoting both protection and progress.

Persistent smoking should be understood not only as an individual behaviour, but also as an indicator of policy limitations. When existing interventions fail to reach certain groups of smokers, harm reduction becomes an important complement to prevention and cessation. Safer nicotine products may reduce exposure to the toxicants associated with combustion, particularly among adults who do not quit through conventional routes. The warning signal is therefore not the existence of alternative nicotine use, but the failure to integrate risk-proportionate strategies into tobacco control.

Brazil does not need another lesson in fear. It needs a serious conversation about evidence, risk and what happens when safer nicotine products are pushed out of legal reach. Education should help people understand why smoking is uniquely dangerous and how non-combustible alternatives differ from cigarettes. Without that clarity, policy can end up defending the very product it claims to defeat.

When four Member States challenge Poland’s nicotine pouch restrictions, the issue is no longer just national policy. It becomes a test of proportionality, evidence and whether the EU can regulate new nicotine products without pushing them into a prohibitionist corner. Nicotine pouches should be controlled responsibly, but restrictions need to reflect relative risk and avoid closing legal pathways away from smoking. A single-market dispute can also be a public health warning.

South Korea's high taxes on nicotine pouches, compared to cigarettes, hinder tobacco harm reduction efforts. In contrast, Sweden's lower taxes on smoke-free alternatives have drastically reduced smoking rates. South Korea's stringent regulations treat all nicotine products like cigarettes, impeding public health goals. Korea's lack of progress highlights the importance of distinguishing between products based on harm. For the EU, decisions on taxation and regulation will impact tobacco control efforts. Following Sweden's approach of targeting harm reduction over consumption could lead to lower smoking rates and healthcare costs. The EU should consider Sweden's model when updating tobacco directives to prioritize public health.

Tax hikes can only go so far if they ignore how people and markets respond. The Philippines’ experience shows that making cigarettes more expensive may reduce use for some, but it can also fuel illicit trade when legal products become unaffordable. Tobacco policy needs more than higher taxes; it needs enforcement, consumer insight and lower-risk alternatives that give smokers a realistic way out. A strategy that prices people into the black market is not the same as reducing harm.